[go: up one dir, main page]

MA30994B1 - Composition de supplement nutritionnnel pour le traitement de maladies oculaires - Google Patents

Composition de supplement nutritionnnel pour le traitement de maladies oculaires

Info

Publication number
MA30994B1
MA30994B1 MA31993A MA31993A MA30994B1 MA 30994 B1 MA30994 B1 MA 30994B1 MA 31993 A MA31993 A MA 31993A MA 31993 A MA31993 A MA 31993A MA 30994 B1 MA30994 B1 MA 30994B1
Authority
MA
Morocco
Prior art keywords
treatment
nutritional supplement
ocular diseases
supplement composition
macular degeneration
Prior art date
Application number
MA31993A
Other languages
English (en)
Inventor
Georg Ludwig Kis
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38024441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30994(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30994B1 publication Critical patent/MA30994B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

LA PRÉSENTE INVENTION PORTE SUR UNE COMPOSITION D'ANTI-OXYDANT ET DE SUPPLÉMENT DE LUTÉINE QUI, ENTRE AUTRES, DIMINUE LA PERTE D'ACUITÉ VISUELLE EN RÉDUISANT LE RISQUE DE DÉVELOPPER UNE DÉGÉNÉRESCENCE MACULAIRE LIÉE À UN STADE TARDIF OU À UN ÂGE AVANCÉ CHEZ LES PERSONNES PRÉSENTANT UNE DÉGÉNÉRESCENCE MACULAIRE PRÉCOCE LIÉE À L'ÂGE.
MA31993A 2006-12-15 2009-06-15 Composition de supplement nutritionnnel pour le traitement de maladies oculaires MA30994B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06126261A EP1932521A1 (fr) 2006-12-15 2006-12-15 Composition de supplément nutritionnel pour le traitement des maladies oculaires

Publications (1)

Publication Number Publication Date
MA30994B1 true MA30994B1 (fr) 2009-12-01

Family

ID=38024441

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31993A MA30994B1 (fr) 2006-12-15 2009-06-15 Composition de supplement nutritionnnel pour le traitement de maladies oculaires

Country Status (22)

Country Link
US (1) US20100028459A1 (fr)
EP (2) EP1932521A1 (fr)
JP (1) JP2010513248A (fr)
KR (1) KR20090089473A (fr)
CN (1) CN101557807A (fr)
AR (1) AR064332A1 (fr)
AU (1) AU2007331432A1 (fr)
BR (1) BRPI0720046A2 (fr)
CA (1) CA2672013A1 (fr)
CL (1) CL2007003630A1 (fr)
CO (1) CO6220929A2 (fr)
EC (1) ECSP099516A (fr)
GT (1) GT200900161A (fr)
MA (1) MA30994B1 (fr)
MX (1) MX2009006306A (fr)
NO (1) NO20092633L (fr)
PE (1) PE20081580A1 (fr)
RU (1) RU2009126735A (fr)
TN (1) TN2009000241A1 (fr)
TW (1) TW200843725A (fr)
WO (1) WO2008071775A1 (fr)
ZA (1) ZA200903862B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8389504B2 (en) * 2008-05-08 2013-03-05 Mead Johnson Nutrition Company Prenatal dietary supplement
WO2010074940A1 (fr) * 2008-12-23 2010-07-01 Alcon Research, Ltd. Compositions et compléments nutritionnels améliorant la santé oculaire et réduisant la réponse inflammatoire de l'oeil
US20130011469A1 (en) 2009-07-23 2013-01-10 U.S. Nutraceuticals, Llc D/B/A Valensa International Krill oil and carotenoid composition, associated method and delivery system
US20110237548A1 (en) * 2009-07-23 2011-09-29 U.S. Nutraceuticals, Llc D/B/A Valensa International Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome using omega choline
US20130295171A1 (en) 2009-07-23 2013-11-07 U.S NUTRACEUTICALS, LLC d/b/a Valensa International Krill oil and reacted astaxanthin composition and associated method
US20110021465A1 (en) * 2009-07-23 2011-01-27 U.S. Nutraceuticals, Llc D/B/A Valensa International Synergistic composition and method of retarding and ameliorating photo induced retinal damage and cataracts while ameliorating dry eye syndrome
JP2014524914A (ja) * 2011-07-07 2014-09-25 ハワード・ファウンデーション・ホールディングス・リミテッド 視覚パフォーマンス及び／若しくは黄斑色素形成の改善、又は視覚パフォーマンス及び／若しくは黄斑色素形成に関連した改善
US9381183B2 (en) 2012-07-18 2016-07-05 Physicians Recommended Nutriceuticals, Llc Methods for improving the quality of the meibum composition of meibomian glands
US10709680B2 (en) 2011-07-18 2020-07-14 Physicians Recommended Nutriceuticals, Llc Methods for treating dry eye
US20210121430A1 (en) 2011-07-18 2021-04-29 Prn Physician Recommended Nutriceuticals, Llc Omega-3 fatty acid supplementation for use in treating dry eye
US9115078B2 (en) 2011-07-18 2015-08-25 Physicians Recommended Nutriceuticals, Llc Compositions for improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands
ES2565402T3 (es) * 2011-09-12 2016-04-04 Tassos GEORGIOU Uso de los ácidos grasos omega para el tratamiento de enfermedades
CN102538980A (zh) * 2012-01-12 2012-07-04 杭州美盛红外光电技术有限公司 热像装置和热像拍摄方法
JP2016185939A (ja) * 2015-03-27 2016-10-27 ロート製薬株式会社 経口組成物
JP2016190829A (ja) * 2015-03-31 2016-11-10 ウィルファーム株式会社 活性型ｄｈａを含む製剤、強化食品、サプリメント並びに化粧品
JP6056114B2 (ja) * 2015-05-30 2017-01-11 富田製薬株式会社 油状物質含有粉末組成物
CN108208804A (zh) * 2018-01-05 2018-06-29 美博迪尔（北京）生物科技有限公司 一种缓解眼睛干涩、抵御蓝光损伤及保护眼底的组合物及其制备方法
CN108096288A (zh) * 2018-01-16 2018-06-01 南京圣诺生物科技实业有限公司 护眼片及其制备方法和应用
EP3886907B1 (fr) * 2018-11-27 2024-10-02 Novaliq GmbH Compositions d'alcane semifluoré comprenant des esters éthyliques d'acides gras oméga-3
CN115551498A (zh) * 2020-03-11 2022-12-30 博士伦爱尔兰有限公司 包含极长链脂肪酸的用于眼睛健康的组合物和方法
WO2025151943A1 (fr) * 2024-01-18 2025-07-24 Moro Peres Nemecio Complément alimentaire particulièrement indiqué pour combattre la dégénérescence maculaire, capsule comprenant ledit complément alimentaire et utilisation de celui-ci

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002320251A1 (en) * 2001-07-05 2003-01-21 Vital Basics, Inc. Compositions for improving mental performance
US6649195B1 (en) * 2002-07-11 2003-11-18 Vitacost.Com, Inc. Eyesight enhanced maintenance composition
US20050112210A1 (en) * 2003-09-12 2005-05-26 Terry Grossman Eye nutritional supplement
WO2005110375A1 (fr) * 2004-05-08 2005-11-24 Paul Edward L Jr Supplément alimentaire pour le traitement des maladies oculaires
DE202005012984U1 (de) * 2005-08-17 2005-11-24 W & B Pharmamarken Gmbh Arzneimittel- und Nahrungsergänzungsmittelkombinationen zur Behandlung von Augenerkrankungen
BRPI0620210A2 (pt) * 2005-12-20 2011-11-01 Alcon Res Ltd composição e processos para a inibição da progressão da degeneração macular e para promover visão saudável

Also Published As

Publication number Publication date
TN2009000241A1 (en) 2010-10-18
CL2007003630A1 (es) 2008-08-08
CA2672013A1 (fr) 2008-06-19
ECSP099516A (es) 2009-08-28
TW200843725A (en) 2008-11-16
EP1932521A1 (fr) 2008-06-18
AR064332A1 (es) 2009-04-01
US20100028459A1 (en) 2010-02-04
BRPI0720046A2 (pt) 2013-12-24
JP2010513248A (ja) 2010-04-30
CN101557807A (zh) 2009-10-14
AU2007331432A1 (en) 2008-06-19
NO20092633L (no) 2009-07-10
PE20081580A1 (es) 2009-01-01
GT200900161A (es) 2009-11-30
ZA200903862B (en) 2010-05-26
EP2094252A1 (fr) 2009-09-02
CO6220929A2 (es) 2010-11-19
KR20090089473A (ko) 2009-08-21
MX2009006306A (es) 2009-06-23
RU2009126735A (ru) 2011-01-20
WO2008071775A1 (fr) 2008-06-19

Similar Documents

Publication Publication Date Title
MA30994B1 (fr) Composition de supplement nutritionnnel pour le traitement de maladies oculaires
IL183284A0 (en) Methods and compositions for treating ocular disorders
WO2006055526A3 (fr) Compositions utiles pour le traitement de maladies neovasculaires oculaires et la degenerescence maculaire
GEP20084520B (en) Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
MY176679A (en) Use of nutritional compositions for preventing disorders
WO2008054200A3 (fr) Utilisation de compositions nutritives pour empêcher des troubles
TNSN05300A1 (en) Treatment with anti-vegf antibodies
AR034220A1 (es) Complemento nutricional para tratar la degeneracion macular
TN2010000201A1 (en) Anti-hepcidin antibodies and uses thereof
WO2008029169A3 (fr) Procédé de traitement de troubles respiratoires
WO2007109236A8 (fr) Empreintes digitales micro-arn pendant une mégacaryocytopoïese
MX2009006342A (es) Composicion de complemento alimenticio para tratamiento de enfermedades oculares.
WO2006091459A3 (fr) Compositions et methodes permettant de traiter la permeabilite vasculaire
MX2009004402A (es) Uso de gen de amiloide serico en el diagnostico y tratamiento de glaucoma e identificacion de agentes anti-glaucoma.
WO2005014814A3 (fr) Aptameres a coiffes 5'- et 3'- et utilisations associees
BRPI0417732A (pt) aplicação de gene amilóide a sérico no diagnóstico e tratamento do glaucoma e identificação de agentes antiglaucoma
MA30485B1 (fr) Aminothiazoles et leurs utilisations
WO2007035092A3 (fr) Vhh destines au diagnostic, a la prevention et au traitement de maladies associees aux agregats proteiques
WO2008039409A3 (fr) Procédés et matériels à utilisation thérapeutique et préventive dans le cadre des maladies du système immunitaire ou des maladies infectieuses
TW200609559A (en) Contact lenses and methods for their design
WO2006012521A3 (fr) Traitement de maladies oculaires
PT1838716E (pt) Di-hidrato de pamoato de olanzapina
WO2007012748A3 (fr) Nouvelles fractions proteiques laitieres et leur utilisation pour la prevention ou le traitement des maladies inflammatoires chroniques
WO2006065968A3 (fr) Nouvelles applications d'agonistes des recepteurs beta-oestrogeniques
BRPI0411427A (pt) formulações de agentes antiinflamatórios não-esteróides para o tratamento de angiogênese ocular patológica